AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.
In the latest trading session, Pfizer (PFE) closed at $40.22, marking a -0.42% move from the previous day.